CN105055342A - Sodium ilaprazole medicine composition freeze-dried powder injection for treating peptic ulcer - Google Patents
Sodium ilaprazole medicine composition freeze-dried powder injection for treating peptic ulcer Download PDFInfo
- Publication number
- CN105055342A CN105055342A CN201510495088.3A CN201510495088A CN105055342A CN 105055342 A CN105055342 A CN 105055342A CN 201510495088 A CN201510495088 A CN 201510495088A CN 105055342 A CN105055342 A CN 105055342A
- Authority
- CN
- China
- Prior art keywords
- ilaprazole
- sodium
- ilaprazole sodium
- dried powder
- peptic ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses a sodium ilaprazole medicine composition freeze-dried powder injection for treating peptic ulcer, and belongs to the technical field of medicines. The sodium ilaprazole medicine composition freeze-dried powder injection comprises sodium ilaprazole and an excipient, wherein the excipient is low molecular dextran; sodium ilaprazole is a novel crystal compound different from that reported in the prior art, and the X-ray powder diffraction pattern of sodium ilaprazole is measured by utilizing Cu-K alpha rays and shown in Figure 1. Experiments prove that the novel crystal sodium ilaprazole compound is high in purity, liquidity and stability, low in impurity content and hygroscopicity, and safe and reliable in clinical application; the sodium ilaprazole medicine composition freeze-dried powder injection prepared by utilizing the novel crystal sodium ilaprazole compound is high in bioavailability and stability; the stability of the sodium ilaprazole medicine composition freeze-dried powder injection remains high after the sodium ilaprazole medicine composition freeze-dried powder injection is compatible with a solvent; the content of insoluble particles is extremely low. Therefore, the sodium ilaprazole medicine composition freeze-dried powder injection is particularly suitable for clinical application.
Description
Technical field
The invention belongs to medical art, relate to a kind of medicine Ilaprazole Sodium composite freeze-dried powder agent for the treatment of peptic ulcer.
Background technology
Ilaprazole, have another name called IY-81149, it is the novel proton pump inhibitor of a kind of irreversible developed by foreign drugmaker of Korea S one, it suppresses helicobacter pylori (HP) effect stronger than omeprazole, effective dose is only 1/4 of omeprazole, not easily develop immunity to drugs, and toxic and side effects is not obvious; Ilaprazole is compared with original like product, causing delayed gastric emptying, parietal cell swelling and the defect significantly after drug withdrawal in gastric acid secretion bounce-back etc. overcoming original like product in varying degrees, the curative effect to dyskinesis sample functional dyspepsia (GERD) and other acid-related diseases can be strengthened simultaneously, and onset is faster, acid suppression better effects if, t1/2 is longer, can continue acid suppression and control night time acid breakthrough; The dependency of its metabolism to CYP2C19 is little, affects little by enzyme gene pleiomorphism.Long half time, whole day maintains higher acid suppression level, and the time of stomach pH>4 obviously extends, and effectively reduces the phenomenon of Control of Nocturnal Gastric Acid Breakthrough; Curative effect is not by the medicine that hepatocyte inner cell pigment isozyme CYP2C19 metabolic polymorphism affects, and individual variation is little; It is that treatment comprises taste-blindness rate, and reflux esophagitis and Zollinger-Ellisonsyndrome syndrome are at interior potent drug for the treatment of with gastric acid-related diseases.
The novel potent proton pump of ilaprazole Shi Li pearl group first listing of the whole world in 2007 suppresses enteric coatel tablets, is applicable to duodenal ulcer and reflux esophagitis.Its acid suppression activity is more than 4 times of omeprazole, and the day dosing of omeprazole enteric-coated preparation is 40mg, and ilaprazole then only needs 5-10mg; Long half time, long action time in body, without CYP2C19 metabolism, also seldom by CYP3A4 enzymes metabolism, to different genotype patient without individual variation; Less adverse effect.For adapting to the patient of digestive tract hemorrhage, playing the feature that ilaprazole Acidinhibitor is strong, making gastric pH reach more than 6 rapidly, hemostatic factor quick acting.
Ilaprazole is alkalescence, and very poor at light, heat, water, oxygen, stable under acidic conditions, the approach of existing solution ilaprazole stability problem mainly comprises the crystal formation changing dosage form or change medicine.
Chinese patent CN102038648B discloses a kind of injection and preparation method for the treatment of peptic ulcer, and selected active component is Ilaprazole Sodium.Said preparation is made up of Ilaprazole Sodium, excipient, antioxidant and/or metal ion chelation agent, and wherein above-mentioned each constituent mass mark is than being ilaprazole 1 part, excipient 1-30, antioxidant 0-10 part and/or metal ion chelation agent 0-0.3 part.Effectively improve the problem of Ilaprazole Sodium stable under acidic conditions difference.But, add sodium thiosulfate in this patent of invention prescription, add the risk of medicine to blood vessel irritation.Simultaneously according to actual production, on the basis ensureing curative effect of medication, solubility and product appearance, the kind of adjuvant and consumption are more few better, are not only conducive to reducing corresponding toxic and side effects, increase Drug safety, can also save production cost.
Patent CN101687848B discloses A, B, E, F, the I crystal of ilaprazole compound.Wherein racemic ilaprazole crystal form A is that in all crystal formations, in aqueous solvent, dissolubility is minimum, but a kind of crystal formation that thermokinetics is the most stable; Other four kinds of crystal formations are derived by diverse ways by crystal form A and obtain.Crystal formation F, compared with crystal form A, is more soluble in aqueous solvent, and the biology of crystal form B and crystal formation F is acceptable poor, and it can be used to prepare depot drug product composition.Which describe the preparation method of crystal form A: 3%NH4OH/ acetonitrile (MeCN) (6.00kg, 15.0 parts) load in flask, adjust the temperature to 5 DEG C (2-8 DEG C), add ilaprazole (0.400kg), stir 1 hour, elimination filtrate, filter cake 3%NH4OH/ acetonitrile (MeCN) (2 × 0.400kg, 2 × 1.00 parts) rinsing.Filter cake load flask, add 0.5%NH4OH/EtOH (0.200kg, 0.500 part) and at 20-25 DEG C concentrating under reduced pressure, until there is no distillation.0.5%NH4OH/EtOH (1.00kg, 2.50 parts) is added again in flask, and dichloromethane (2.40kg, 6.00 parts).The solution obtained is evaporated to ca.1.2L (3.00 amount) at 20-25 DEG C.Add 0.5%NH4OH/EtOH (0.200kg, 0.500 part) again, be adjusted to 5 DEG C (2-8 DEG C), stir 45 minutes.With 0.5%NH4OH/EtOH (0.200kg, 0.500 part) after elimination filtrate, EtOH (0.200kg, 0.500 part) and MTBE (2 × 0.200kg, 2 × 0.500 parts) rinsing.Filtration cakes torrefaction 2 hours, then under maximum temperature is 53 DEG C of conditions vacuum drying 92 hours, obtain racemic ilaprazole crystal form A.
Patent CN103172618A discloses Ilaprazole crystal form X, which describe the preparation method of crystal form X: be dissolved in by ilaprazole in the mixed solvent of halogenated alkane and absolute methanol, again above-mentioned solvent is slowly added in ether solvent, stir until crystallize out, crystal Precipitation Temperature is 25 DEG C, wherein said halogenated alkane is the one in dichloromethane, chloroform, and the volume ratio of halogenated alkane and ether is 1:25-10, and the volume ratio of halogenated alkane and absolute methanol is 1:1.
Patent CN104370886A discloses Ilaprazole crystal form M, which describes the preparation method of M crystal formation: 1) be dissolved in 5-20mL chloroform by 1-2g ilaprazole; 2) by above-mentioned solution evaporated under reduced pressure below 30 DEG C, after evaporate to dryness, add 5-40mL ethyl acetate, dissolve, stir, crystallize at least 20 minutes; 3) filtered by crystal, filter cake ethyl acetate is washed, 20-35 DEG C of drying, obtains ilaprazole M crystal formation.
But it is lower still to there is drug effect in above-mentioned crystal formation, the problem of less stable, the present inventor starts with from the research of Ilaprazole Sodium solid chemical material existence, a kind of Ilaprazole Sodium compound crystal has been prepared through a large amount of tests, surprisingly find through overtesting, this crystal compound purity is high, good fluidity, good stability, impurity content is low, not easily moisture absorption, clinical practice is safe and reliable, the lyophilized injectable powder drug effect utilizing this crystal compound obtained and bioavailability high, good stability, good with solvent compatibility rear stability, particulate matter content is extremely low, be very suitable for clinical practice.
Summary of the invention
Goal of the invention of the present invention is to provide a kind of medicine Ilaprazole Sodium composite freeze-dried powder agent for the treatment of peptic ulcer.
In order to complete object of the present invention, the technical scheme of employing is:
Treat a medicine Ilaprazole Sodium composite freeze-dried powder agent for peptic ulcer, comprise Ilaprazole Sodium and excipient, described Ilaprazole Sodium is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
As preferably, with parts by weight, described compositions is made up of the Ilaprazole Sodium of 1 weight portion, the excipient of 9-11 weight portion.
As preferably, with parts by weight, described compositions by the Ilaprazole Sodium of 1 weight portion, 10 weight portions excipient form.
As preferably, the preparation method of described compositions comprises the following steps:
Get ilaprazole sodium compound of the present invention, use water for injection stirring and dissolving, add the excipient of recipe quantity, adjust ph, be then stirred to pH constant after, mend inject water to 150 times that liquor capacity is Ilaprazole Sodium weight, then active carbon coarse filtration is used, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filters into sterilizing room, measure pH and content qualified after, fill, pressure half plug, puts into the freeze drying box being cooled to-50 DEG C, lyophilization, tamponade outlet, rolls lid.
As preferably, described excipient is low molecular dextran.
As preferably, described lyophilization is: first-50 DEG C of pre-freezes 2 hours, then dry 13 hours of reduced vacuum under-40 DEG C of conditions, finally 30 DEG C of high temperature dryings 6 hours.
As preferably, described adjustment pH is 8.0 ~ 9.0.
The preparation method of the ilaprazole sodium crystal in the present composition comprises the following steps:
1) dimethyl formamide and isopropyl alcohol are mixed with mixed solution A with the volume ratio of 1:4;
2) Ilaprazole Sodium crude drug is got, add the mixed solution A that step 1) is prepared, the volume of wherein said mixed solution A is 10ml:1g with the ratio of the quality of Ilaprazole Sodium, stirs and makes all to dissolve in backward gained solution to add 0.1%g/ml activated carbon decolorizing, filtration, obtain settled solution;
3) diisopropyl ether and dichloromethane are mixed with mixed solution B with the volume ratio of 1:4.5;
4) under room temperature, be to step 2 at power under the ultrasonic field of 0.8KW) add mixed solution B in the settled solution of gained, wherein the addition of mixed solution B is 5 times of the volume of mixed solution A, finish closedown ultrasonic field, be cooled to-5 DEG C, leave standstill 4 hours, crystallize out, drying obtains described ilaprazole sodium compound.
Below technical scheme of the present invention is made further explanation:
The present invention is by the precise controlling to crystallization condition, and prepared a kind of ilaprazole sodium novel crystal form unlike the prior art, the X-ray powder diffraction pattern of this ilaprazole sodium crystal unlike the prior art.Simultaneously due to the ins and outs of this crystal formation, find through test, this crystal compound purity is high, good fluidity, good stability, impurity content is low, not easily moisture absorption, clinical practice is safe and reliable, the lyophilized injectable powder drug effect utilizing this crystal compound obtained and bioavailability high, good stability, good with solvent compatibility rear stability, particulate matter content is extremely low, is very suitable for clinical practice.
Accompanying drawing explanation
Fig. 1 is the X-ray powder diffraction that the ilaprazole sodium crystal of the embodiment of the present invention 1 preparation uses the measurement of Cu-K alpha ray to obtain.
Detailed description of the invention
Below by specific embodiment, summary of the invention of the present invention is described in further detail, but does not therefore limit content of the present invention.
embodiment 1:the preparation of ilaprazole sodium crystal
1) dimethyl formamide and isopropyl alcohol are mixed with mixed solution A with the volume ratio of 1:4;
2) Ilaprazole Sodium crude drug is got, add the mixed solution A that step 1) is prepared, the volume of wherein said mixed solution A is 10ml:1g with the ratio of the quality of Ilaprazole Sodium, stirs and makes all to dissolve in backward gained solution to add 0.1%g/ml activated carbon decolorizing, filtration, obtain settled solution;
3) diisopropyl ether and dichloromethane are mixed with mixed solution B with the volume ratio of 1:4.5;
4) under room temperature, be to step 2 at power under the ultrasonic field of 0.8KW) add mixed solution B in the settled solution of gained, wherein the addition of mixed solution B is 5 times of the volume of mixed solution A, finish closedown ultrasonic field, be cooled to-5 DEG C, leave standstill 4 hours, crystallize out, drying obtains described ilaprazole sodium compound.
The X-ray powder diffraction pattern that the ilaprazole sodium crystal prepared uses the measurement of Cu-K alpha ray to obtain as shown in Figure 1.
embodiment 2:the preparation of ilaprazole sodium freeze-dried powder injection:
Prescription: with parts by weight as table 1
Table 1 Ilaprazole Sodium composition prescription
Get ilaprazole sodium compound of the present invention, use water for injection stirring and dissolving, add the low molecular dextran of recipe quantity, adjust ph is 8.0-9.0, be then stirred to pH constant after, mend inject water to 150 times that liquor capacity is Ilaprazole Sodium weight, then active carbon coarse filtration is used, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after, fill, pressure half plug, put into the freeze drying box being cooled to-50 DEG C, lyophilization, tamponade outlet, rolls lid.
Described lyophilization is: first-50 DEG C of pre-freezes 2 hours, then dry 13 hours of reduced vacuum under-40 DEG C of conditions, finally 30 DEG C of high temperature dryings 6 hours.
embodiment 3:the preparation of ilaprazole sodium freeze-dried powder injection:
Prescription: with parts by weight as table 2
Table 2 Ilaprazole Sodium composition prescription
Get ilaprazole sodium compound of the present invention, use water for injection stirring and dissolving, add the low molecular dextran of recipe quantity, adjust ph is 8.0-9.0, be then stirred to pH constant after, mend inject water to 150 times that liquor capacity is Ilaprazole Sodium weight, then active carbon coarse filtration is used, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after, fill, pressure half plug, put into the freeze drying box being cooled to-50 DEG C, lyophilization, tamponade outlet, rolls lid.
Described lyophilization is: first-50 DEG C of pre-freezes 2 hours, then dry 13 hours of reduced vacuum under-40 DEG C of conditions, finally 30 DEG C of high temperature dryings 6 hours.
embodiment 4:the preparation of ilaprazole sodium freeze-dried powder injection:
Prescription: with parts by weight as table 3
Table 3 Ilaprazole Sodium composition prescription
Get ilaprazole sodium compound of the present invention, use water for injection stirring and dissolving, add the low molecular dextran of recipe quantity, adjust ph is 8.0-9.0, be then stirred to pH constant after, mend inject water to 150 times that liquor capacity is Ilaprazole Sodium weight, then active carbon coarse filtration is used, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after, fill, pressure half plug, put into the freeze drying box being cooled to-50 DEG C, lyophilization, tamponade outlet, rolls lid.
Described lyophilization is: first-50 DEG C of pre-freezes 2 hours, then dry 13 hours of reduced vacuum under-40 DEG C of conditions, finally 30 DEG C of high temperature dryings 6 hours.
comparative example 1:the preparation (with reference to patent WO2011071314A2) of Ilaprazole crystal form A
10g Ilaprazole Sodium is dissolved in 200mL dehydrated alcohol, neutralizes, stirring at normal temperature 2h with the alcoholic solution containing acetic acid 10%, and filter, with the washing with alcohol filter cake of 40mL50%, 40 DEG C of dry 12h, obtain off-white color solid 8.5g, yield 85%.
comparative example 2:the preparation (with reference to patent WO2011071314A2) of Ilaprazole crystal form B
10g ilaprazole is dissolved in the methanol of 50mL and the mixed solvent of dichloromethane, slowly drips 250mL ether, stirring at normal temperature 45min, filters, filter cake washed with diethylether, and 30 DEG C are dried 12h, off-white color solid 8.5g, yield 85%.
comparative example 3:the preparation (referenced patent US20110082174) of Ilaprazole crystal form E
10g ilaprazole crystal form A is dissolved in 700mL methanol drip in the solution of a triethylamine.Solid supersound process is dissolved.Membrane filtration is in vial, and bottle covers mouth with the aluminium foil having 5 apertures and then at room temperature evaporates.Obtain dark green solid after 6 days, obtain Ilaprazole crystal form E.
comparative example 4:the preparation (referenced patent US20110082174) of Ilaprazole crystal form F
Getting ilaprazole crystal form A 10g is dissolved in 200mL dichloromethane, drips a triethylamine.Solution evaporates with under room temperature after membrane filtration with 0.2.Obtaining slight colored solid after about 1 day, is Ilaprazole crystal form F.
comparative example 5:the preparation of Ilaprazole crystal form I
Getting ilaprazole crystal form A 10g is dissolved in 200mL methanol, drips a triethylamine, freezing after membrane filtration.About 2 days final vacuum collecting by filtration white solids, this solid is Methanol Solvate.White solid is put into vial, and opening is placed in room temperature under vacuo, and obtaining white solid after about 1 day is crystalline form I.
comparative example 6:the preparation (referenced patent CN103172618A) of Ilaprazole crystal form X
At 25 DEG C, in the single port bottle of 250m1, add l0g ilaprazole, add 100m1 dichloromethane, 100m1 absolute methanol successively, agitating solution dissolves completely to ilaprazole, then is transferred in constant pressure funnel by solution.Slowly be added drop-wise in 250m1 ether by above-mentioned ilaprazole mixed solution, control temperature of reaction system in dropping process in the scope of 25 scholar 2 DEG C, time for adding controls between 25-30min.After dropwising, keep temperature 25 DEG C of agitating solutions 40 minutes crystallizes.Decompress filter, with 150mL ether washing leaching cake, dry 24 hours of ambient temperature in vacuum, obtaining off-white powder, is Ilaprazole crystal form X, and productive rate is 84%.
comparative example 7:the preparation (referenced patent CN104370886A) of Ilaprazole crystal form M
1) 1g ilaprazole is dissolved in 20mL chloroform, lucifuge rapid solution;
2) by above-mentioned solution evaporated under reduced pressure below 30 DEG C, 20mL ethyl acetate is added after evaporate to dryness, lucifuge rapid solution, lucifuge stirring and crystallizing 1h after dissolving;
3) filtered by crystal, filter cake ethyl acetate washes three times, 28 DEG C of dryings.Obtain off-white color crystalline powder 0.789g, productive rate 78.9%.
experimental example 1:stability test
The stability difference of the present invention and Ilaprazole crystal form of the prior art is described below by way of contrast experiment.
1, temperatures involved Factor Experiment
Get comparative example 1-7 (Ilaprazole crystal form A respectively, B, E, F, I.X, M) and the Ilaprazole sodium crystal form of the embodiment of the present invention 1 at temperature 60 C, place 10 days under the condition of relative humidity 75%, respectively the 0th, 5, its outward appearance, color and luster measure impurity content, the results detailed in Table 4 are observed in sampling in 10 days.
Table 4 temperatures involved Factor Experiment result
Result shows, from table 4, and ilaprazole A, B, E, F, the placement under the high temperature conditions of I, X, M crystal formation is after 10 days, from character, see ilaprazole A in appearance, B, E, F, I darken, and ilaprazole X and M does not have change substantially, Ilaprazole sodium crystal form of the present invention is compared with other Ilaprazole crystal form, and the content placing its impurity after 10 days is under the high temperature conditions starkly lower than other Ilaprazole crystal form, and stability is better.
2, high humidity influence factor experiment
Get 1g comparative example 1-7 (Ilaprazole crystal form A, B, E respectively, F, I, X, and the Ilaprazole sodium crystal form of embodiment 1 M), in the exsiccator containing saturated potassium nitrate solution, (25 DEG C, relative humidity 92.5%) are placed 10 days, respectively the 0th, 5, sampling in 10 days, observes its outward appearance, color and luster measure impurity content, the results detailed in Table 5.
Table 5 high humidity influence factor experimental result
Result shows, from table 5, and ilaprazole A, B, E, F, the placement under conditions of high humidity of I, X, M crystal formation is after 10 days, from character, see ilaprazole A in appearance, B, E, F, I darken, and ilaprazole X and M does not have change substantially, Ilaprazole sodium crystal form of the present invention is compared with other Ilaprazole crystal form, and the content placing its impurity after 10 days is under conditions of high humidity starkly lower than other Ilaprazole crystal form, and stability is better.
3, high light influence factor experiment
Get 1g comparative example 1-7 Ilaprazole crystal form A respectively, B, E, F, I, X, M) and embodiment 1 Ilaprazole sodium crystal form, place 10 days in the lighting box that illumination is the daylight lamp of (4500 scholar 500) lx, sampling in 0th, 5,10 days respectively, observe its outward appearance, color and luster measure impurity content, the results detailed in Table 6.
Table 6 high light influence factor experimental result
Result shows, from table 6, and ilaprazole A, B, E, F, the placement of I, X, M crystal formation under intense light conditions is after 10 days, from character, see ilaprazole A in appearance, B, E, F, I darken, and ilaprazole X and M does not have change substantially, Ilaprazole sodium crystal form of the present invention is compared with other Ilaprazole crystal form, and the content placing its impurity after 10 days under intense light conditions is starkly lower than other Ilaprazole crystal form, and stability is better.
experimental example 2:ilaprazole crystal form pharmacodynamic experiment
To the pharmacodynamic experiment of the mouse gastric ulcer caused by aspirin
Get male and female half and half mice 90, body weight 18-22g, be divided into 9 groups at random, group is divided into: group 1: blank group; Group 2: Ilaprazole crystal form A3mg/kg dosage group; Group 3: Ilaprazole crystal form B3mg/kg dosage group; Group 4: Ilaprazole crystal form E3mg/kg dosage group; Group 5: Ilaprazole crystal form F3mg/kg dosage group; Group 6: Ilaprazole crystal form I3mg/kg dosage group; Group 7: Ilaprazole crystal form X3mg/kg dosage group, group 8: Ilaprazole crystal form M3mg/kg dosage group, group 9: Ilaprazole sodium crystal form 3mg/kg dosage group of the present invention, after water 24h is can't help in mice fasting, group 2-6 presses the corresponding medicine of 0.2ml/10g body weight gavage respectively, and the blank group of group 1 presses the body weight gavage distilled water of 0.2ml/10g.The equal gavage aspirin 150mg/kg of each group after mice administration 30min, mice is put to death after 4h, open mouse peritoneal, ligation cardia and pylorus and inject in gastral cavity through coat of the stomach 1% formalin 2ml, stomach is taken out in immersion 1% formalin, 30min tailing edge greater gastric curvature is cut open, and a situation arises to observe stomach ulcer under anatomic microscope, calculates ulcer area and ulcer inhibition rate.Concrete outcome is as shown in table 7:
Ulcer inhibition rate account form:
Table 7 Ilaprazole crystal form is on the impact of the gastric ulcer caused by aspirin in mouse
Result shows: from table 7, and the group 9 i.e. ulcer average area of Ilaprazole sodium crystal form 3mg/kg dosage group of the present invention is 0.41mm
2, ulcer inhibition rate is 92.38%, and compared with other Ilaprazole crystal form, the ulcer area of Ilaprazole sodium crystal form of the present invention reduces obviously, and ulcer inhibition rate obviously raises.
experimental example 3:bioavailability study
This experimental example has investigated the bioavailability of ilaprazole sodium compound by pharmacokinetic.
Trial drug: commercially available Ilaprazole Sodium, ilaprazole sodium compound of the present invention are made lyophilized injectable powder respectively.
Experimental animal: Beagle dog.
Dosage and mode: dosage is respectively 10mg, morning injection administration after animal fasting, each cleaning intersects administration after one week.
Sample collecting: respectively at before animals administer and administration after different time (0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,8,12h) get blood by dog forelimb, get blood at every turn and be about 2ml, add and use in the centrifuge tube of anticoagulant heparin in advance, the insulating foam box being built-in with ice bag is put at once interior standing 20 minutes after blood specimen collection, 3000rpm low-temperature centrifugation is separated plasma after 10 minutes,-40 DEG C of preservations, to be checked.
The pretreatment of sample: plasma sample thawed at room temperature, the blood plasma getting 0.2ml joins in 1.5ml centrifuge tube, then adds 100 μ L50mM ammonium formate solution, mark liquid in the omeprazole of 50mL280ng/ml, vortex mixed 30s, then the t-butyl methyl ether adding 0.6ml, vortex shakes 2 minutes, centrifugal (13,000 rev/min) after 10min, get supernatant 30 DEG C of heating in water bath N2 and volatilize, residue 200 μ l mobile phases dissolve, get 10 μ l and carry out LC/MS/MS analysis, record chromatogram.
The oral pharmacokinetic studies data of the commercially available ilaprazole of table 8
The oral medicine of table 9 ilaprazole sodium compound of the present invention is for dynamic experiment data
Pharmacokinetic results is in table 8 and table 9.From table 8 and table 9, the blood drug level of ilaprazole sodium compound of the present invention is significantly higher than the blood drug level of commercially available ilaprazole, shows that Ilaprazole Sodium crystalline compound of the present invention makes effective ingredient bioavailability in vivo be significantly improved.
Claims (8)
1. treat the medicine Ilaprazole Sodium composite freeze-dried powder agent of peptic ulcer for one kind, it is characterized in that: described compositions comprises Ilaprazole Sodium and excipient, described Ilaprazole Sodium is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
2. the medicine Ilaprazole Sodium composite freeze-dried powder agent for the treatment of peptic ulcer according to claim 1, is characterized in that: with parts by weight, and described compositions is made up of the Ilaprazole Sodium of 1 weight portion, the excipient of 9-11 weight portion.
3. the medicine Ilaprazole Sodium composite freeze-dried powder agent for the treatment of peptic ulcer according to claim 2, is characterized in that: with parts by weight, described compositions by the Ilaprazole Sodium of 1 weight portion, 10 weight portions excipient form.
4. prepare a method for the medicine Ilaprazole Sodium composite freeze-dried powder agent of the arbitrary described treatment peptic ulcer of claim 1-3, it is characterized in that, the preparation method of described compositions comprises the following steps:
Get ilaprazole sodium compound, use water for injection stirring and dissolving, add the excipient of recipe quantity, adjust ph, be then stirred to pH constant after, mend inject water to 150 times that liquor capacity is Ilaprazole Sodium weight, then active carbon coarse filtration is used, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filters into sterilizing room, measure pH and content qualified after, fill, pressure half plug, puts into the freeze drying box being cooled to-50 DEG C, lyophilization, tamponade outlet, rolls lid.
5., according to the medicine Ilaprazole Sodium composite freeze-dried powder agent of the arbitrary described treatment peptic ulcer of claim 1-3, it is characterized in that: described excipient is low molecular dextran.
6. the preparation method of the medicine Ilaprazole Sodium composite freeze-dried powder agent for the treatment of peptic ulcer according to claim 4, it is characterized in that: described lyophilization is for first-50 DEG C of pre-freezes 2 hours, then dry 13 hours of reduced vacuum under-40 DEG C of conditions, finally 30 DEG C of dryings 6 hours.
7. the preparation method of the medicine Ilaprazole Sodium composite freeze-dried powder agent for the treatment of peptic ulcer according to claim 4, is characterized in that: described adjustment pH is 8.0-9.0.
8. the medicine Ilaprazole Sodium composite freeze-dried powder agent for the treatment of peptic ulcer according to claim 1, it is characterized in that, the preparation method of the crystal of described Ilaprazole Sodium comprises the following steps:
1) dimethyl formamide and isopropyl alcohol are mixed with mixed solution A with the volume ratio of 1:4;
2) Ilaprazole Sodium crude drug is got, add the mixed solution A that step 1) is prepared, the volume of wherein said mixed solution A is 10ml:1g with the ratio of the quality of Ilaprazole Sodium, stirs and makes all to dissolve in backward gained solution to add 0.1%g/ml activated carbon decolorizing, filtration, obtain settled solution;
3) diisopropyl ether and dichloromethane are mixed with mixed solution B with the volume ratio of 1:4.5;
4) under room temperature, be to step 2 at power under the ultrasonic field of 0.8KW) add mixed solution B in the settled solution of gained, wherein the addition of mixed solution B is 5 times of the volume of mixed solution A, finish closedown ultrasonic field, be cooled to-5 DEG C, leave standstill 4 hours, crystallize out, drying obtains described ilaprazole sodium compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510495088.3A CN105055342A (en) | 2015-08-13 | 2015-08-13 | Sodium ilaprazole medicine composition freeze-dried powder injection for treating peptic ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510495088.3A CN105055342A (en) | 2015-08-13 | 2015-08-13 | Sodium ilaprazole medicine composition freeze-dried powder injection for treating peptic ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105055342A true CN105055342A (en) | 2015-11-18 |
Family
ID=54485029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510495088.3A Withdrawn CN105055342A (en) | 2015-08-13 | 2015-08-13 | Sodium ilaprazole medicine composition freeze-dried powder injection for treating peptic ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105055342A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107141281A (en) * | 2017-06-28 | 2017-09-08 | 珠海赛隆药业股份有限公司 | A kind of left-handed Iprazole sodium compound and its pharmaceutical composition and preparation method |
| CN107311984A (en) * | 2017-07-19 | 2017-11-03 | 珠海赛隆药业股份有限公司 | A kind of dextrorotation Iprazole sodium compound and its pharmaceutical composition and preparation method |
| CN109053685A (en) * | 2018-06-22 | 2018-12-21 | 丽珠医药集团股份有限公司 | A kind of pharmaceutical composition and preparation method thereof containing Ilaprazole Sodium |
| WO2019242181A1 (en) | 2018-06-22 | 2019-12-26 | 丽珠医药集团股份有限公司 | Pharmaceutical composition containing ilaprazole or salt thereof and preparation method therefor |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101066435A (en) * | 2007-06-05 | 2007-11-07 | 陈旭龙 | Iprazole containing medicine |
| WO2008083333A1 (en) * | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of racemic ilaprazole |
| WO2008083319A1 (en) * | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
| CN101426371A (en) * | 2005-12-16 | 2009-05-06 | 塔克达北美医药品公司 | Pharmaceutical compositions of ilaprazole |
| CN102058593A (en) * | 2010-12-27 | 2011-05-18 | 吴赣英 | Combination medicament of ilaprazole sodium and preparation process thereof |
| CN102746275A (en) * | 2012-06-21 | 2012-10-24 | 丽珠医药集团股份有限公司 | Crystallization-type ilaprazole sodium and preparation method thereof |
| CN102746277A (en) * | 2012-06-21 | 2012-10-24 | 丽珠医药集团股份有限公司 | Crystal-form ilaprazole sodium and preparation method thereof |
| CN102746276A (en) * | 2012-06-21 | 2012-10-24 | 丽珠医药集团股份有限公司 | Ilaprazole sodium crystal form and preparation method thereof |
| CN103204842A (en) * | 2012-01-13 | 2013-07-17 | 丽珠医药集团股份有限公司 | Crystalline Ilaprazole sodium hydrate and preparation method thereof |
| CN103204843A (en) * | 2012-01-13 | 2013-07-17 | 丽珠医药集团股份有限公司 | Crystalline Ilaprazole sodium ethylate and preparation method thereof |
-
2015
- 2015-08-13 CN CN201510495088.3A patent/CN105055342A/en not_active Withdrawn
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101426371A (en) * | 2005-12-16 | 2009-05-06 | 塔克达北美医药品公司 | Pharmaceutical compositions of ilaprazole |
| WO2008083333A1 (en) * | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of racemic ilaprazole |
| WO2008083319A1 (en) * | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
| WO2008083341A1 (en) * | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Crystalline forms of solvated ilaprazole |
| CN101066435A (en) * | 2007-06-05 | 2007-11-07 | 陈旭龙 | Iprazole containing medicine |
| CN102058593A (en) * | 2010-12-27 | 2011-05-18 | 吴赣英 | Combination medicament of ilaprazole sodium and preparation process thereof |
| CN103204842A (en) * | 2012-01-13 | 2013-07-17 | 丽珠医药集团股份有限公司 | Crystalline Ilaprazole sodium hydrate and preparation method thereof |
| CN103204843A (en) * | 2012-01-13 | 2013-07-17 | 丽珠医药集团股份有限公司 | Crystalline Ilaprazole sodium ethylate and preparation method thereof |
| CN102746275A (en) * | 2012-06-21 | 2012-10-24 | 丽珠医药集团股份有限公司 | Crystallization-type ilaprazole sodium and preparation method thereof |
| CN102746277A (en) * | 2012-06-21 | 2012-10-24 | 丽珠医药集团股份有限公司 | Crystal-form ilaprazole sodium and preparation method thereof |
| CN102746276A (en) * | 2012-06-21 | 2012-10-24 | 丽珠医药集团股份有限公司 | Ilaprazole sodium crystal form and preparation method thereof |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107141281A (en) * | 2017-06-28 | 2017-09-08 | 珠海赛隆药业股份有限公司 | A kind of left-handed Iprazole sodium compound and its pharmaceutical composition and preparation method |
| CN107141281B (en) * | 2017-06-28 | 2020-04-14 | 珠海赛隆药业股份有限公司 | Levalprazole sodium compound and pharmaceutical composition and preparation method thereof |
| CN107311984A (en) * | 2017-07-19 | 2017-11-03 | 珠海赛隆药业股份有限公司 | A kind of dextrorotation Iprazole sodium compound and its pharmaceutical composition and preparation method |
| CN107311984B (en) * | 2017-07-19 | 2020-04-14 | 珠海赛隆药业股份有限公司 | Dextro-ilaprazole sodium compound, and pharmaceutical composition and preparation method thereof |
| CN109053685A (en) * | 2018-06-22 | 2018-12-21 | 丽珠医药集团股份有限公司 | A kind of pharmaceutical composition and preparation method thereof containing Ilaprazole Sodium |
| WO2019242181A1 (en) | 2018-06-22 | 2019-12-26 | 丽珠医药集团股份有限公司 | Pharmaceutical composition containing ilaprazole or salt thereof and preparation method therefor |
| CN109053685B (en) * | 2018-06-22 | 2020-09-22 | 丽珠医药集团股份有限公司 | Pharmaceutical composition containing ilaprazole sodium and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100484525C (en) | Pantoprazole sodium freeze-dried powder injection and preparing method thereof | |
| CN105055342A (en) | Sodium ilaprazole medicine composition freeze-dried powder injection for treating peptic ulcer | |
| CN102875531B (en) | A kind of (R)-lansoprazole anhydrous crystal forms and preparation method thereof | |
| CN103254174A (en) | Lansoprazole compound and pharmaceutical composition thereof | |
| CN103054797B (en) | Pharmaceutical composition of pantoprazole sodium and preparation method thereof | |
| CN102285970B (en) | Esomeprazole compound, preparation method and pharmaceutical compoistion | |
| CN110312705B (en) | Crystal form of GFT-505, preparation method and application thereof | |
| CN104784146A (en) | Pharmaceutical Ilaprazole sodium composition for treating peptic ulcer | |
| CN104922080A (en) | Pharmaceutical ilaprazole sodium freeze-dried powder injection composition for treating digestive system diseases | |
| CN102796078B (en) | Pantoprazole compound, preparation methods and pharmaceutical preparations thereof | |
| CN105055343A (en) | Ilaprazole sodium composition freeze-dried powder injection serving as medicine for treating stomach diseases | |
| CN105030772A (en) | Ilaprazole sodium composition serving as medicine for treating digestive diseases | |
| WO2016202212A2 (en) | Omeprazole sodium compound prepared by using particle processing for molecular assembly and morphological optimization of crystalline products, and preparation of said compound | |
| CN104370886A (en) | Ilaprazole crystal form as well as preparation method and application thereof | |
| CN102746272B (en) | Esomeprazole sodium polymorph, preparation method and application thereof | |
| CN101250180A (en) | Amorphous S-pantoprazole sodium, preparation method and use thereof | |
| CN112778290B (en) | Addition salt of S1P1 receptor agonist, crystal form and pharmaceutical composition thereof | |
| CN105147682A (en) | Pharmaceutical ilaprazole sodium composition for treating gastric ulcer | |
| CN105147680A (en) | Drug ilaprazole sodium composition resisting to gastric acid secretion | |
| CN105213389A (en) | The medicine ilaprazole composition of sodium that a kind of gastric acid inhibitory produces | |
| ES2969740T3 (en) | Pharmaceutical composition containing ilaprazole and a salt thereof and a method of preparation thereof | |
| CN105106121A (en) | Drug ilaprazole sodium composition dry suspension for treating digestive system diseases | |
| CN105106150A (en) | Drug ilaprazole sodium composition tablets for treating peptic ulcer | |
| CN104761543A (en) | Ilaprazole compound for treating peptic ulcer and preparation method thereof | |
| CN109053685B (en) | Pharmaceutical composition containing ilaprazole sodium and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151118 |
|
| WW01 | Invention patent application withdrawn after publication |